Dialix oxalate plus 90 chews

Therapeutic indications

dialix oxalate plus 90 chews is indicated for the treatment and control of external parasite infestations in dogs, providing targeted action against fleas and ticks and constituting a valid support in integrated control strategies. In particular, the product is indicated for the treatment of flea infestations (Ctenocephalides spp.) with the aim of interrupting the reproductive cycle of the parasite and reducing parasitic pressure in the domestic environment. Regular use helps prevent the recurrence of flea infestations and is indicated as part of the management of flea allergic dermatitis (FAD), as it reduces the animal's exposure to the flea antigens that trigger the allergic reaction.

For ticks, dialix oxalate plus 90 chews is intended for the treatment of infestations caused by species commonly present in the dog's area of ​​residence; the product tends to rapidly reduce the number of ticks present on the host and helps to limit the possibility of transmission of pathogens transmitted by these blood-sucking insects. It is important to remember that, for parasites to be exposed to the active ingredient, it is necessary for them to attach to the host and begin to bite: therefore, in the period immediately following the attack, the possibility of transmission of pathogens already present in the arthropod population cannot be excluded.

dialix oxalate plus 90 chews is also indicated as a support in the treatment of parasitic skin conditions such as demodicosis and sarcoptic mange, where compatible with the vet's clinical assessment. For demodicosis, the product can be used as part of a long-term therapeutic protocol, continuing administration until the skin scrapings become negative. In the case of sarcoptic mange, regular and prolonged administration according to the recommended schedule contributes to the eradication of the infesting stages and the clinical resolution of the associated dermatological signs.

Composition

The formulation of dialix oxalate plus 90 chews consists of chewable tablets specially prepared for good acceptance by dogs. Each tablet contains the active ingredient in a stabilized form as an oxalate salt, integrated with excipients aimed at improving the palatability, the physical structure of the tablet and the stability of the active ingredient. The choice of excipients is aimed at guaranteeing a consistency suitable for chewing, a pleasant taste and safe preservation of the product over time.

The excipients present inside the tablets facilitate daily administration, giving the tablet organoleptic characteristics (flavor, aroma and consistency) which increase spontaneous acceptance by the animal. The formulation has been designed to minimize the risk of product breakage during handling and to ensure that the active ingredient is delivered homogeneously in each administration unit.

Information on the chemical nature of the active ingredient, on the concentration and on the analytical specifications is available to the healthcare professional: the qualitative composition of the formulation has been designed to comply with current regulations and to optimize the safety and tolerability profile in the intended subjects. For a correct evaluation of the composition, the veterinarian is recommended to consult the detailed technical information available in the product's technical documentation.

Contraindications

Do not use dialix oxalate plus 90 chews in case of known hypersensitivity to the active ingredient or to any of the excipients contained in the formulation. In the presence of known allergic reactions or previous intolerances to similar products, the veterinarian must evaluate the risk/benefit ratio before prescribing the treatment. The use of the product is not recommended in animals with acute severe clinical conditions that are not stabilized or in animals showing signs of systemic disease until a diagnosis and adequate management have been carried out.

As regards use in young animals, in the absence of specific safety data for certain age groups, it is advisable to avoid administration in extremely young puppies or in subjects below the minimum recommended weight without a prior clinical evaluation by the veterinarian. In case of pregnancy or lactation, the use of the product must be carefully evaluated by the professional, taking into consideration the clinical state of the mother and the potential benefits for the animal's health.

Do not administer the product at the same time as other antiparasitic formulations containing active ingredients that could interact: the veterinarian will evaluate possible pharmacological interactions with other ongoing treatments, including systemic or local therapies for concomitant pathologies. In the presence of serious adverse signs or allergic reactions, immediately discontinue treatment and contact your veterinarian for appropriate therapeutic and supportive measures.

Safety of the drug for the species

The safety of dialix oxalate plus 90 chews in dogs has been considered in the context of the intended use: since the mechanism of action often requires contact of the parasite with the host to expose the active ingredient, it is not possible to completely exclude the risk of transmission of pathogens from ectoparasites to the animal, especially if administration occurs in the presence of parasites already attached. For this reason it is recommended to use the product as part of a global external parasite control strategy and to adopt complementary environmental measures when necessary.

During preclinical studies and controlled trials, the reported tolerability profiles indicate that the majority of subjects tolerate administration well, with adverse events usually of a mild and transient nature such as mild gastrointestinal disorders or temporary changes in eating behavior. Severe neurological signs or systemic reactions are rare but require immediate attention and reporting to your veterinarian. Administration to subjects with pre-existing pathologies should be carefully evaluated, balancing the potential benefits of parasite control with the general state of the animal.

To maximize safety of use, the veterinarian must consider the patient's complete clinical history, any ongoing therapies and predisposing conditions that may affect the pharmacokinetics of the active ingredient. In the event of accidental overdose, veterinary personnel will provide appropriate clinical indications for symptomatic and supportive treatment.

Precautions

Special precautions for use in animals: before starting treatment with dialix oxalate plus 90 chews, the veterinarian must evaluate the general state of health of the animal, including any concomitant pathologies (hepatic, renal, neurological or immune) and the presence of currently ongoing systemic therapies that could lead to interactions. In the absence of consolidated safety data for animals in particular physiological categories, the use in pregnant or lactating subjects and in very young puppies must be carried out only after careful clinical evaluation of the risk/benefit ratio.

Precautions for the person administering the product: handle the tablets with care, avoiding prolonged contact with the skin in case of known sensitivity to the excipients. To reduce the risk of accidental human exposure, remove only one tablet from the blister at a time and place the blister with the remaining tablets in the original carton. Keep out of reach of children and pets not intended for treatment. In case of accidental ingestion or prolonged contact with the skin causing reactions, consult a doctor and take the product packaging with you to allow a correct evaluation.

Wash your hands after handling the product. Avoid contact of the product with eyes; in case of contact, rinse thoroughly with water and consult a healthcare professional if symptoms persist. Store the product in a cool, dry place, away from direct light, as indicated in the general storage conditions for veterinary pharmaceutical products.

Method of administration

Dialix Oxalate Plus 90 Chews tablets are chewable and have been formulated to be palatable to most dogs. Administration can take place by offering the tablet directly to the dog as a reward or by placing it on top of or mixed with the usual food if the subject is reluctant to accept it. If the dog refuses the tablet administered individually, it is possible to break it down and mix its contents with a small quantity of palatable food to facilitate ingestion, always checking that the entire dosage is administered.

It is important to follow the dosing instructions provided by the veterinarian, who will base the dosage on the animal's body weight and specific clinical conditions. The tablet must be administered orally and is not intended for topical use. If you experience immediate vomiting after administration, contact your veterinarian to determine whether a repeat dose or alternative administration measures are necessary.

To encourage adherence to treatment, it is recommended to establish a fixed time for monthly administration, integrating it into the routine of the animal and the owner. Regularity in administration is essential to guarantee continuous protection against infestations by external parasites and to reduce the risk of relapses.

Treatment program

For the control of flea and tick infestations, the recommended regimen involves periodic monthly administrations. The exact frequency and duration of treatment depend on the local epidemiological situation, the level of environmental infestation and the clinical assessment of the veterinarian. In areas or periods of greater parasitic pressure, continuous administration may be indicated to maintain an effective protective barrier against new infestations; in contexts with low exposure the strategy can be adapted on a seasonal and clinical basis.

For the treatment of demodicosis, continue the monthly administration of the product until two negative skin scrapings are obtained one month apart, unless otherwise clinically indicated. More severe or chronic cases may require extended monthly treatments and a multimodal approach that addresses any predisposing underlying conditions. For sarcoptic mange, monthly administration is recommended for at least two consecutive months; based on the clinical response and diagnostic checks it may be necessary to continue with additional administrations to ensure complete elimination of the parasite.

Since infestation control also involves the environment, it is recommended to adopt complementary measures such as regular cleaning of environments, treatment of cohabiting animals when indicated and management of areas where animals spend time. The adoption of a coordinated program between veterinarian and owner optimizes therapeutic results and reduces the risk of reinfestation.

Target species

Species targeted for treatment: dogs. dialix oxalate plus 90 chews is formulated exclusively for use in dogs and should not be used in other animal species without specific veterinary evaluation. For cohabiting animals of different species, the veterinarian will provide appropriate recommendations in relation to parasite management and the possible need for separate or alternative treatments.

Before starting treatment, always check that the subject falls within the indications for use and that there are no contraindications or risk factors that would advise against administration. The veterinary doctor is the point of reference for adapting the therapeutic protocol to the specific clinical needs of the animal, monitoring the response to treatment and promptly managing any adverse effects or the need to modify the therapeutic program.